Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone

Drug and Alcohol Dependence

Volumn 133, Issue 1, 2013, Pages 266-269

  Gaalema, Diann E ^a,b   Heil, Sarah H ^a,b   Badger, Gary J ^a   Metayer, Jerilyn S ^c   Johnston, Anne M ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence syndrome; Opioids; Pregnancy; Treatment

Indexed keywords

BUPRENORPHINE; FENTANYL; METHADONE; MORPHINE;

ARTICLE; BIRTH WEIGHT; CHILD CARE; CHILDBIRTH; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; MEDICAL RECORD REVIEW; NEWBORN; OPIATE ADDICTION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEX DIFFERENCE; TIME; WITHDRAWAL SYNDROME;

BUPRENORPHINE; METHADONE; NAS; NEONATAL ABSTINENCE SYNDROME; OPIOIDS; PREGNANCY; TREATMENT;

BIRTH WEIGHT; BUPRENORPHINE; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84884413455     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.06.004     Document Type: Article

References (22)

1. Binder T., Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro. Endocrinol. Lett. 2008, 29:80-86.
2. Brown H.L., Britton K.A., Mahaffey D., Brizendine E., Hiett A.K., Turnquest M.A. Methadone maintenance in pregnancy: a reappraisal. Am. J. Obstet. Gynecol. 1998, 179:459-463.
3. Doberczak T.M., Kandall S.R., Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J. Pediatr. 1991, 118:933-937.
4. Dysart K., Hsieh H.C., Kaltenbach K., Greenspan J.S. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J. Perinat. Med. 2007, 35:344-346.
5. Ebner N., Rohrmeister K., Winklbaur B., Baewert A., Jagsch R., Peternell A., Thau K., Fischer G. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. 2007, 87:131-138.
6. Finnegan L.P., Kaltenbach K. Neonatal abstinence syndrome. Primary Pediatric Care 1992, 1367-1378. Mosby, St. Louis. 2nd ed. R.A. Hoekelman, S.B. Friedman, N.M. Nelson, M.L. Weitzman, M.H. Wilson (Eds.).
7. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101:275-281.
8. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., Arria A., Stine S.M., Martin P.R., Jones H.E. Differences in the profile of neonatal abstinence syndrome signs in methadone- vs. buprenorphine-exposed infants. Addiction 2012, 107:S53-S62.
9. Hudak M.L., Tan R.C., The Committee on Drugs, The Committee on Fetus and Newborn Neonatal drug withdrawal. Pediatrics 2012, 129:e540-e560.
10. Jansson L.M., Dipietro J.A., Elko A., Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J. Matern. Fetal Neonatal Med. 2007, 20:677-685.
11. Jansson L.M., Velez M., Harrow C. The opioid exposed newborn: assessment and pharmacologic management. J. Opioid Manage. 2009, 5:47-55.
12. Johnson R.E., Strain E.C., Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003, 70:S59-S77.
13. Jones H.E., O'Grady K.E., Malfi D., Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am. J. Addict. 2008, 17:372-386.
14. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
15. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet. Gynecol. Clin. North Am. 1998, 25:139-151.
16. Lawless J.F. Statistical Model and Methods for Lifetime Data 2003, John Wiley & Sons, New York. 2nd ed.
17. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend. 2006, 82:250-257. Groupe d'Etudes Grossesse et Addictions (GEGA).
18. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. JAMA 1998, 280:1936-1943.
19. Nelson W. Applied Life Data Analysis 1982, John Wiley & Sons, New York.
20. O'Connor A.B., O'Brien L., Alto W.A. Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy?. J. Perinat. Med. 2013, 11:1-3.
21. Olsen I.E., Groveman S.A., Lawson M.L., Clark R.H., Zemel B.S. New intrauterine growth curves based on United States data. Pediatrics 2010, 125:e214-e224.
22. Walsh S.L., Eissenberg T. The clinical pharmacology of buprenorphine extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003, 70:S13-S27.